PUBLISHER: DelveInsight | PRODUCT CODE: 1226650
PUBLISHER: DelveInsight | PRODUCT CODE: 1226650
"OLUMIANT Drug Insight and Market Forecast - 2032" report provides comprehensive insights about OLUMIANT for Rheumatoid Arthritis in the 7MM. A detailed picture of the OLUMIANT for Rheumatoid Arthritis in the 7MM, i.e., United States, EU4 (Germany, France, Italy, Spain), and the United Kingdom, and Japan for the study period 2019-2032 is provided in this report along with a detailed description of the OLUMIANT for Rheumatoid Arthritis. The report provides insight about mechanism of action, dosage and administration, as well as research and development activity including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the OLUMIANT market forecast, analysis for Rheumatoid Arthritis in the 7MM, descriptive analysis such as SWOT, analysts' views, comprehensive overview of market competitors, and brief about emerging therapies in Rheumatoid Arthritis.
OLUMIANT (Barticinib) is an immunosuppressant that is indicated for use in inflammatory and autoimmune diseases, or, in other terms, it is defined as a Janus kinase (JAK) inhibitor used to treat adults with moderate-to-severe Rheumatoid Arthritis (RA) who have not responded well enough to or could not tolerate at least one medicine called a tumor necrosis factor (TNF) antagonist. This novel agent achieved its approval on the basis of well-conducted late-stage clinical trials in countries like the US, Europe, and Japan. OLUMIANT is approved with a Boxed Warning for the risk of serious infections, malignancies, and thrombosis.
Currently, OLUMIANT is conducting a trial (NCT04870203) in combination with adalimumab in RA. Apart from that, the company is also conducting a post marketing study to compare the safety of baricitinib versus tumor necrosis factor (TNF) inhibitors with respect to venous thromboembolic events (VTEs) when given to participants with RA.
The report provides insights into:
The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.
OLUMIANT Analytical Perspective by DelveInsight
This report provides a detailed market assessment of OLUMIANT in Rheumatoid Arthritis in the 7MM, i.e., United States, EU4 and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2023 to 2032.
The report provides the clinical trials information of OLUMIANT for Rheumatoid Arthritis covering trial interventions, trial conditions, trial status, start and completion dates.
Key Questions